Lintzeris Nicholas
Turning Point Alcohol and Drug Centre and Australian National University, Victoria, Australia.
Drug Alcohol Rev. 2002 Mar;21(1):39-45. doi: 10.1080/09595230220119309.
This study aimed to establish a buprenorphine regime suitable for the short-term management of out-patient heroin withdrawal using an open-label, single-group case series. Eighteen dependent injecting heroin users underwent an 8-day withdrawal episode with supervised dosing of sublingual Subutex tablets. Buprenorphine doses were titrated daily over a 5-day period. Fifteen subjects (83%) completed the 5-day regime, and 14 (78%) completed the 8-day withdrawal episode. The mean doses ((SD) were 6.1 (1.2) mg on day 1; 9.6 (1.7) mg on day 2; 10.1 (1.9) mg on day 3; 8.9 (2.0) mg on day 4; 4.1 (1.5) mg on day 5; and a total regime dose of 38.9 (5.8) mg. Withdrawal severity was mild, with minimal rebound upon the cessation of dosing. Five subjects reported no heroin use, and five subjects reported using on only one occasion during the 8 days. An out-patient buprenorphine regime is recommended.
本研究旨在通过开放标签的单组病例系列,建立一种适用于门诊海洛因戒断短期管理的丁丙诺啡治疗方案。18名依赖注射海洛因的使用者接受了为期8天的戒断期,期间舌下含服丁丙诺啡片并接受监督给药。丁丙诺啡剂量在5天内每日滴定。15名受试者(83%)完成了为期5天的治疗方案,14名(78%)完成了为期8天的戒断期。平均剂量((标准差))第1天为6.1(1.2)毫克;第2天为9.6(1.7)毫克;第3天为10.1(1.9)毫克;第4天为8.9(2.0)毫克;第5天为4.1(1.5)毫克;总治疗方案剂量为38.9(5.8)毫克。戒断症状较轻,停药后反弹最小。5名受试者报告未使用海洛因,5名受试者报告在8天内仅使用过一次。推荐采用门诊丁丙诺啡治疗方案。